ArticleUnited European gastroenterology journal2018
Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites.
Article in United European gastroenterology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Specific Items of Enhanced Recovery After Surgery for Liver Surgery in Cirrhotic Patients: A Systematic Review.World journal of surgery · 2025Pooled it
- Multiple Concomitant Precipitating Factors of Hepatic Encephalopathy Are Associated With a Poor Prognosis in Patients With Cirrhosis Admitted to Intensive Care Unit.United European gastroenterology journal · 2025Article
- Prevalence and clinical impact of alcohol withdrawal syndrome in alcohol-associated hepatitis and the potential role of prophylaxis: a multinational, retrospective cohort study.EClinicalMedicine · 2023Article
- Old and New Precipitants in Hepatic Encephalopathy: A New Look at a Field in Continuous Evolution.Journal of clinical medicine · 2023Review
- Why zolpidem increases the risk of falls and fractures in patients with cirrhosis.JHEP reports : innovation in hepatology · 2022Article
- The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis.United European gastroenterology journal · 2021Article
- Managing medicines in alcohol-associated liver disease: a practical review.Australian prescriber · 2021Review
- A multidisciplinary approach to the management of liver disease and alcohol disorders in psychiatric settings (Review).Experimental and therapeutic medicine · 2021Review
- Shunt-Induced Hepatic Encephalopathy in TIPS: Current Approaches and Clinical Challenges.Journal of clinical medicine · 2020Review
- Improving Medication-Related Outcomes in Chronic Liver Disease.Hepatology communications · 2020Review
- Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis.Hepatology (Baltimore, Md.) · 2019Article
- Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.Alimentary pharmacology & therapeutics · 2019Article
- Management of Alcohol Withdrawal Syndrome in Patients with Alcoholic Liver Disease.Journal of clinical and experimental hepatologyReview
- Integrated Care of Alcohol-Related Liver Disease.Journal of clinical and experimental hepatologyArticle
- Antidepressants in People With Chronic Liver Disease and Depression: When Are They Warranted and How to Choose the Suitable One?Journal of clinical and experimental hepatologyReview
- Retrospective evaluation of medication appropriateness in older adults with hepatic cirrhosis.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited evidence to support the belief that benzodiazepines increase cirrhosis patients' risk of hepatic encephalopathy (HE).
objectiveWe aimed to examine the association between benzodiazepine use and HE development in cirrhosis patients.
methodsWe used data on 865 cirrhosis patients with ascites from three trials to study the effect of benzodiazepine use on development of first-time HE. For each patient, we classified periods of benzodiazepine use by the number of days since initiation. We used Cox regression to compare the risk of HE in current benzodiazepine users vs. non-users adjusting for confounders.
resultsCirrhosis patients were not at increased risk of HE for the first two days of benzodiazepine use, but then faced a five-fold increased risk of HE during days 3 to 10 of benzodiazepine use. The risk of HE was not increased for those who had been using benzodiazepines for more than 28 days.
conclusionCirrhosis patients who had begun using benzodiazepines between 3 and 10 days previously had a markedly increased risk of developing first-time HE. Cirrhosis patients who had been using benzodiazepines for just one or two days or continued use for more than 28 days did not have such an excess risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.